Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays

Oncogene

Volumn 32, Issue 29, 2013, Pages 3470-3476

  Gujral, T S ^a,b   Karp, R L ^a   Finski, A ^a,c   Chan, M ^a   Schwartz, P E ^d   Macbeath, G ^a,b   Sorger, P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d Protein Biotechnologies Inc   (United States)

Author keywords

AXL; Breast cancer; Cell signaling; MET; Reverse phase protein arrays; Tumor lysate

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; P21 ACTIVATED KINASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR;

ARTICLE; BREAST CANCER; BREAST CELL; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVERSE PHASE PROTEIN ARRAY; SIGNAL TRANSDUCTION; TUMOR CELL DESTRUCTION;

BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84880917870     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.378     Document Type: Article

References (56)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799. (Pubitemid 39070849)
2. Kolch W, Pitt A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 2010; 10: 618-629.
3. Sevecka M, MacBeath G. State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods 2006; 3: 825-831. (Pubitemid 44445830)
4. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Gene 2001; 20: 1981-1989. (Pubitemid 32458030)
5. Tibes R, Qiu YH, Lu Y, Hennessy B, Andreeff M, Mills GB et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006; 5: 2512.
6. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003; 3: 2142-2146. (Pubitemid 37414080)
7. VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin I et al. Reversephase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007; 7: 625-633. (Pubitemid 47547727)
8. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010; 6: 129-151.
9. Sevecka M, Wolf-Yadlin A, Macbeath G. Lysate microarrays enable highthroughput, quantitative investigations of cellular signaling. Mol Cell Proteomics 2011; 10: M110 005363.
10. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007; 6: 820-832. (Pubitemid 46554552)
11. Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 2006; 6: 2964-2971. (Pubitemid 43806395)
12. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reversephase lysate microarrays. Proc Natl Acad Sci USA 2003; 100: 14229-14234. (Pubitemid 37499219)
13. Lin Y, Huang R, Cao X, Wang SM, Shi Q, Huang RP. Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate. Clin Chem Lab Med 2003; 41: 139-145. (Pubitemid 36336702)
14. Spruessel A, Steimann G, Jung M, Lee SA, Carr T, Fentz AK et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 2004; 36: 1030-1037. (Pubitemid 38747367)
15. Sevecka M, Wolf-Yadlin A, MacBeath G. Lysate microarrays enable highthroughput, quantitative investigations of cellular signaling. Mol Cell Proteomics 2011; 10: M110 005363.
16. Luckert K, Gujral TS, Chan M, Joos TO, Sorger PK, Macbeath G et al. A dual arraybased approach to assess the abundance and posttranslational modification state of signaling proteins. Sci Signal 2012; 5: pl1.
17. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 2011; 8: 11.
18. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 2010; 16: 2852-2860.
19. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010; 5: 1894-1904.
20. Janes KA, Reinhardt HC, Yaffe MB. Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell 2008; 135: 343-354.
21. Goentoro L, Kirschner MW. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell 2009; 36: 872-884.
22. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21: 2889-2895. (Pubitemid 46621838)
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
24. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993; 170: 31-35. (Pubitemid 23130581)
25. Herrero J, Valencia A, Dopazo J. A hierarchical unsupervised growing neural network for clustering gene expression patterns. Bioinformatics 2001; 17: 126-136. (Pubitemid 32208521)
26. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J et al. Inference of patientspecific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010; 26: i237-i245.
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
28. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol 2003; 224: 149-157.
29. Pe'er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell 2011; 144: 864-873.
30. Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MCU et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004; 10: 6143.
31. Liu G, Fong E, Zeng X. GNCPro: navigate human genes and relationships through net-walking. Adv Exp Med Biol 2010 253-259.
32. Menashe I, Maeder D, Garcia-Closas M, Figueroa JD, Bhattacharjee S, Rotunno M et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res 2010; 70: 4453.
33. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113: 678-682. (Pubitemid 40038747)
34. Underiner TL, Herbertz T, Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem 2010; 10: 7-27.
35. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008; 68: 1905.
36. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010; 107: 1124.
37. Bowers PM, Pellegrini M, Thompson MJ, Fierro J, Yeates TO, Eisenberg D. Prolinks: a database of protein functional linkages derived from coevolution. Genome Biol 2004; 5: R35.
38. Marcotte EM, Pellegrini M, Thompson MJ, Yeates TO, Eisenberg D. A combined algorithm for genome-wide prediction of protein function. Nature 1999; 402: 83-86.
39. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 2011; 130: 663-679.
40. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17: 295-304. (Pubitemid 44038616)
41. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
42. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-10111. (Pubitemid 44672064)
43. Lim CT, Zhang Y. Bead-based microfluidic immunoassays: the next generation. Biosens Bioelectron 2007; 22: 1197-1204. (Pubitemid 46157004)
44. Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. Gas6 anti-apoptotic signaling requires NF-kappa B activation. J Biol Chem 2001; 276: 31738-31744.
45. Previdi S, Abbadessa G, Dalo F, France DS, Broggini M. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012; 11: 214-223.
46. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30: 1436-1448.
47. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70: 1544-1554.
48. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008; 68: 1905-1915. (Pubitemid 351416577)
49. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128. (Pubitemid 41713383)
50. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 2012; 30: 1352-1360.
51. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007; 26: 3909-3919. (Pubitemid 46884299)
52. Birchmeier C, Birchmeier W, Gherardi E, Woude GFV. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925. (Pubitemid 37493640)
53. Mood K, Saucier C, Bong YS, Lee HS, Park M, Daar IO. Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor. Mol Biol Cell 2006; 17: 3717.
54. Sam MR, Elliott BE, Mueller CR. A novel activating role of SRC and STAT3 on HGF transcription in human breast cancer cells. Mol Cancer 2007; 6: 69.
55. Wojcik E, Sharifpoor S, Miller N, Wright T, Watering R, Tremblay E et al. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006; 25: 2773-2784.
56. Yeh CY, Shin SM, Yeh HH, Wu TJ, Shin JW, Chang TY et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 2011; 11: 139.